

Molecular BioSystems

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.


You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/molecularbiosystems

Diminazene or berenil is known to be AT-rich DNA minor groove binder with micromolar dissociation constant. Here, we show that DMZ binds to G-quadruplexes with K_d as low as 1 nM.



Diminazene or berenil, a classic duplex minor groove binder, binds to G-quadruplexes with low nanomolar dissociation constants and the amidine groups are also critical for G-quadruplex binding.

Jie Zhou^a, Vu Le^b, Dimpy Kalia^a, Shizuka Nakayama^a, Clinton Mikek^b,

Edwin A. Lewis^{b*} and Herman O. Sintim^{a,c*}

^aDepartment of Chemistry and Biochemistry, University of Maryland, College Park, MD
20742, USA.

^bDepartment of Chemistry, Mississippi State University, Mississippi State, MS 39762.

^cProgram in Oncology, University of Maryland Marlene and Stewart Greenebaum Cancer
Center, 22 S. Greene Street, Baltimore, Maryland 21201.

elewis@chemistry.msstate.edu; hsintim@umd.edu

ABSTRACT

G-quadruplexes have shown great promise as chemotherapeutic targets, probably by inhibiting telomere elongation or downregulating oncogene expression. There have been avalanches of G-quadruplex ligands developed over the years but only a few have drug-like properties. Consequently only a few G-quadruplex ligands have entered clinical trials as cancer chemotherapeutic agents. The DNA minor groove ligand, berenil (diminazene aceturate or DMZ), is used to treat animal trypanosomiasis and hence its toxicological profile is already known, making it an ideal platform to engineer into new therapeutics. Herein, using a plethora of biophysical methods including UV, NMR, MS and ITC, we show that DMZ binds to several G-quadruplexes with a K_d of ~ 1 nM. This is one of the strongest G-quadruplex binding affinities reported to date and is 10^3 tighter than the berenil affinity for an AT-rich duplex DNA. Structure-activity-relationship studies demonstrate that the two amidine groups on DMZ are important for binding to both G-quadruplex and duplex DNA. This work reveals that DMZ or berenil is not as selective for AT-rich duplexes as originally thought and that some of its biological effects could be manifest through G-quadruplex binding. The DMZ scaffold represents a good starting point to develop new G-quadruplex ligands for cancer cell targeting.

INTRODUCTION

Both DNA and RNA can form many secondary structures, such as G-quadruplex¹⁻³, triplex^{4,5}, i-motif^{6,7}, and a biological role for these polymorphs, especially G-quadruplexes⁸⁻¹⁰, has been suggested. There are ~ 3,760,000 guanine-rich regions in the human genome, which have the potential to form G-quadruplexes^{11,12}, including those at the telomere end¹³ and promoter regions of some cancer-related genes¹⁰. Guanine tracts in RNA are known to form G-quadruplexes *in vivo*^{3,14-16} but the formation of G-quadruplexes in chromosomal DNA has been a matter of debate due to the fact that the guanine tracts in chromosomal DNA can also form duplexes with complementary tracts of cytosines. After many years of fierce debate regarding a biological role for DNA G-quadruplexes *in vivo*, acceptance is now growing that DNA G-quadruplexes might indeed form *in vivo* and that there could be biological consequences of G-quadruplex formation in chromosomal DNA. Firstly, it has been demonstrated that fluorogenic G-quadruplex-specific ligands could become fluorescent inside cells, especially during cell division, when single stranded regions of chromosomal DNA are created during DNA replication^{17,18}. Secondly, seminal works by the laboratories of Pluckthun¹⁹ and Balasubramanian²⁰ resulted in the engineering of G-quadruplex-specific antibodies, which have been used to provide compelling evidence that G-quadruplexes form *in vivo*. Additionally, biophysical approaches (mainly NMR^{21,22} and DEER/ENDOR^{23,24}) have demonstrated that synthetic G-rich oligonucleotides could form G-quadruplex structures *in vivo*.

If G-quadruplex formation *in vivo* has a biological consequence, then small molecules that target and stabilize these structures could have therapeutic value. In animal chromosomes, the telomerase enzyme (which is up-regulated in certain cancers) is responsible for maintaining the telomere length thereby rendering cancer cells immortal^{25,26}. The telomere is G-rich and has been shown via many biophysical experiments to be capable of forming G-quadruplexes²⁷⁻³⁰. Many compounds that bind to G-quadruplexes have been shown to inhibit the extension of the DNA

substrate by telomerase and some have even shown interesting anti-proliferative properties when added to cancer cells³¹⁻³⁵. In addition to telomeres, G-quadruplexes are present in the promoter regions of a number of cancer-related genes such as *c-myc*³⁶, *BCL-2*³⁷, *KRAS*³⁸, *c-kit*³⁹ and *VEGF*⁴⁰, where they are involved in the regulation of transcription of these genes by disrupting binding of transcription factors^{41,42}.

In light of these potential important biological roles of G-quadruplexes, there is high interest in discovering G-quadruplex-selective ligands for both fundamental studies (for example, fluorescent ligands that will allow for studying G-quadruplexes *in vivo*) and also drug-like molecules that will allow for selective targeting of G-quadruplexes related to cancer^{17,32,43,44} and other diseases⁴⁵. In this manuscript, we reveal that DMZ, which has been shown to bind to the minor groove of AT-rich DNA with a micromolar dissociation constant, binds to G-quadruplexes with a nanomolar dissociation constant, i.e. 3 orders of magnitude stronger affinity for G-quadruplexes than AT-rich duplexes. The DMZ scaffold is therefore a good starting point to develop potent G-quadruplex ligands.

MATERIAL AND METHODS

General

4-Aminobenzamidine dihydrochloride, aniline and diminazene aceturate (DMZ or Berenil) were purchased from Aldrich. All triazenes were stored at 4 °C and in dark since significant decomposition of triazenes was observed if stored at room temperature and in presence of light. Sequences of DNA used in this study are shown in Table 1. Purified oligonucleotides 22-mer *c-kit1*, 18-mer *VEGF*, 23-mer *bcl-2 2345*, 15-mer *TBA* and 20-mer 8bp *AT* were purchased from IDT and analyzed for purity before use. Purified WT 27-mer *bcl-2*, WT 24-mer *c-myc*, WT 22-

mer human telomere *hTel* were purchased from Midland Oligos (Midland, TX) and used without further purification.

DNA stock solutions were prepared by reconstituting the lyophilized oligonucleotide into 20 mM Tris buffer with a salt concentration of 100 mM KCl and a pH of 7.2. Approximately 2 mL of the oligonucleotide was dialyzed (1000 Mw cutoff membrane) against three changes of buffer solution (1 L, 24 h each) at 4 °C. The concentrations of stock DNA solutions were verified using UV-Vis. G-Quadruplex DNAs were annealed by quickly heating the sample to 100 °C, holding at 100 °C for ten minutes then slowly cooling to 5 °C, over a three hour period. Molar extinction coefficients of the DNAs were determined using a nearest-neighbor method for single stranded DNA⁴⁸. The extinction coefficients at 260 nm for the WT 27-mer *bcl-2*, WT 24-mer *c-myc*, WT 22-mer human telomere *hTel* sequences are 267,200 M⁻¹cm⁻¹, 248,100 M⁻¹cm⁻¹, and 228,500 M⁻¹cm⁻¹ respectively⁴⁹⁻⁵¹. The extinction coefficient at 260 nm for the 7 base pair hairpin with A₂T₂ (7bp *HP•AT*) and the 7 base pair hairpin without A₂T₂ (7bp *HP*) are 165,200 M⁻¹cm⁻¹ and 159,200 M⁻¹cm⁻¹ respectively. Cell culture grade water purchased from Corning was used for all experiments.

Synthesis of Triazene-1 and Triazene-2

Triazene-1: To a cooled (0 °C) and stirred suspension of 4-aminobenzamidine dihydrochloride (1.0 g, 4.80 mmol) in water (6 mL) and concentrated hydrochloric acid (1 mL), a solution of sodium nitrite (0.36 g, 5.28 mmol) in water (1 mL) was added dropwise and the mixture was stirred for 20 minutes. To the resulting diazonium solution, a solution of aniline (0.43 mL, 4.80 mmol) in MeOH (1 mL) was added followed by addition of saturated aqueous sodium acetate (6 mL). After being stirred at 0 °C for 1 h, the resultant yellow solid was filtered off, washed with brine, dried and crystallized with MeOH/acetone (1:2, 20 mL) to afford analytically pure product (1.2 g, 84%) as an acetate salt. ¹H NMR (DMSO-d₆, 400 MHz) δ 7.87 – 7.83 (m, 2H), 7.57 – 7.47

(m, 4H), 7.47 – 7.42 (m, 2H), 7.31 – 7.26 (m, 1H), 1.72 (s, 3H). ^{13}C NMR (DMSO- d_6 , 100 MHz,) δ 177.1, 165.8, 148.9, 148.4, 130.2, 130.1, 127.4, 123.4, 120.5, 116.1, 25.8. HRMS (ESI $^+$) m/z calcd. for $\text{C}_{13}\text{H}_{14}\text{N}_5$ $[\text{M}+\text{H}]^+$ 240.1249, found 240.1248.

Triazene-2: Following the procedure described above for the Triazene-1, diazonium solution of aniline (0.5 mL, 5.47 mmol) was treated with aniline (0.5 mL, 5.47 mmol) to afford Triazene-2 (1.1 g, 85%), as a yellow solid. ^1H NMR (CDCl_3 , 400 MHz) δ 7.47 – 7.39 (m, 8H), 7.20 (tt, J = 6.9, 1.5 Hz, 2H). ^{13}C NMR (DMSO- d_6 , 100 MHz,) δ 150.7, 142.6, 130.1, 127.7, 123.1, 121.6, 114.9. HRMS (ESI $^+$) m/z calcd. for $\text{C}_{12}\text{H}_{12}\text{N}_3$ $[\text{M}+\text{H}]^+$ 198.1031, found 198.1031.

NMR spectra for synthesized compounds were recorded with a Bruker AV-400 or Bruker DRX-400. ^1H -NMR chemical shifts are reported as (δ) in ppm and are calibrated according to residual solvent peaks. ^1H NMR coupling constants (J values) are reported in Hertz (Hz). ^{13}C -NMR chemical shifts are reported as ppm relative to residual solvent peak. High-resolution mass spectra (HRMS) for synthesized compounds were recorded with JEOL AccuTOF-CS (ESI positive, needle voltage 1800~2400 eV).

UV titration studies of DNA with the triazene ligands, DMZ and Triazene-1

UV measurements for titration studies were done using a JASCO V-630 spectrophotometer. Fluorescence measurements for the displacement assay were done using a Varian Cary Eclipse fluorimeter. The molar extinction coefficients at 260 nm for 22-mer *c-kit1*, 18-mer *VEGF*, 23-mer *bcl-2 2345*, 15-mer *TBA* and 20-mer 8bp *AT* are as follows 226,700 $\text{M}^{-1}\text{cm}^{-1}$, 169,800 $\text{M}^{-1}\text{cm}^{-1}$, 227,300 $\text{M}^{-1}\text{cm}^{-1}$, 143,300 $\text{M}^{-1}\text{cm}^{-1}$ and 205,500 $\text{M}^{-1}\text{cm}^{-1}$, respectively. The concentration of ligands used in this study was 10 μM and the DNA concentrations were 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, and 150 μM . The buffer contained 250 mM KCl, 50 mM Tris-HCl (at pH 7.5). The following quadruplex DNA were tested: *c-kit1*, *VEGF*, *bcl-2 2345*, and *TBA*. Duplex DNA (8bp *AT*) was also tested. The sample was first heated up to 95 $^\circ\text{C}$ for 5 min without the

ligand and then cooled down to room temperature in 15 min. The ligand was then added and the mixture was incubated at 4 °C for ~12 h before recording the data. In case of Triazene-1 and Triazene-2, the sample mixture contained 1% DMSO.

NMR measurements for DNA binding of triazene ligands

NMR measurements for the binding studies were done using Bruker Avance III HD 800 spectrometer equipped with Cryo-Probe. The procedures used in the binding studies were described previously⁴⁶. The ligand concentration was 150 μM, and that of the DNA (*c-kit1* or 8bp *AT*) was 300 μM. The buffer used was 10 mM potassium phosphate (pH 7.5) containing 137 mM NaCl, 1 mM EDTA, and also contained 10 % D₂O. The sample was initially heated up to 95 °C for 5 min without the ligand and then cooled down to room temperature in 15 min. Subsequently, the sample was incubated at 4 °C for ~12 h without the ligand (for G-quadruplex formation). Then, the ligand was added and incubated for 2 h before the NMR measurement (25 °C).

(Note: Because of the high concentrations being used for the NMR, incubating the DNA/ligand for longer periods caused precipitation, probably due to G-quadruplex polymer formation, which is catalyzed by the ligand).

Isothermal titration calorimetry

ITC experiments were performed using a VP-ITC calorimeter (GE-Heathcare). A typical ITC experiment involved the addition of 28 (10 μL) injections of a nominal 1 mM ligand solution into ~ 1.5 mL of a dilute DNA solution (10 μM). All ITC titration experiments were done at 25 °C. Corrected titration curves were obtained by subtracting the blank titration data from the ITC-data for the ligand-DNA titrations. The corrected ITC titrations were fit to a multiple independent sites binding model using a nonlinear regression algorithm, CHASM, developed in our laboratory⁴⁷.

Circular Dichroism (CD)

CD titration experiments were performed with an Olis DSM-20 spectropolarimeter (Bogart, GA). All measurements were done at 25 °C using a 1 cm quartz cuvette and covering a spectral range of 220 - 420 nm. All DNA samples were prepared such that they had a nominal absorbance of less than 1.0 at 260 nm. Stock solutions of the ligand were added in small amount to reach a molar ratio of 1:1, 3:1, 6:1, and 10:1 of ligand per equivalence of DNA.

Electrospray Ionization Mass Spectrometry

ESI-MS experiments on the triazene/DNA complexes were carried out on a Bruker MicrOTOFQ mass spectrometer. Data acquisition was set to operate in negative ion mode. All experiments were performed in 50 mM ammonium acetate buffer containing 20% HPLC grade methanol and adjusted with 1 N KOH solution to reach pH of 7.0. The WT *hTel* 22-mer G-quadruplex sample was prepared at a concentration of approximately 10 μ M in the ammonium acetate buffer and was exhaustively dialyzed. Stock solutions of DMZ and Triazene-1 were prepared in the final dialysate buffer at concentration as high as 300 μ M. The ESI-MS samples were prepared by mixing the DNA and ligand stock solutions to yield a mixture containing excess of each ligand per equivalence of DNA. The MS capillary voltage was set to +3500 V, dry N₂ gas flow was adjusted to 0.5 L/min at 110 °C, and the G-quadruplex/ligand samples were directly infused into the MS by using a kD Scientific syringe pump set to a flow rate of 200 μ L/hour. Data processing was performed by using the Bruker Daltonics Data Analysis program.

RESULTS AND DISCUSSION

Recently, there has been considerable interest in repurposing drugs for new therapeutic indications^{52,53}. Along this line, others have been interested in repurposing DNA duplex minor

groove binders for targeting G-quadruplexes⁵⁴⁻⁵⁷. Compounds that bind minor grooves of DNA duplexes have a track record of clinical efficacy for many indications including animal trypanosomiasis and babesiosis⁵⁸. Because there are numerous toxicological data for these drugs, using them as starting points for the development of G-quadruplex-selective ligands appears to be a reasonable proposition. Curiously, although several duplex minor groove binders have been tested for G-quadruplex binding, DMZ a prototypical AT-rich minor groove binder, which is used clinically to treat animal trypanosomiasis has not been thoroughly investigated for G-quadruplex binding. To date there is only a single report, from our laboratory, that demonstrated that DMZ aggregates the dinucleotide, c-di-GMP, into an ill-defined supramolecular aggregate (probably containing G-quadruplexes) via an uncharacterized mechanism⁵⁹.

DMZ as a G quadruplex ligand




Figure 1: Structures of DMZ, Triazene-1, and Triazene-2.

Table 1. Sequences of DNA and their abbreviations used in the study

Abbreviation	Sequence (5' to 3')
7bp <i>HP</i> *	GCAGTCC TCTCGGACTGC
7bp <i>HP-AT</i> *	GCAATTCTCTCGAATTGC
8bp <i>AT</i> *	CGAATTTC AAAAGAAATTTCG
<i>TBA</i>	GGTTGGTGTGGTTGG
<i>VEGF</i>	GGGCGGGCCGGGGCGGG
<i>hTel</i>	AGGGTTAGGGTTAGGGTTAGGG
<i>c-kit1</i>	AGGGAGGGCGCTGGGAGGAGGG
<i>c-myc</i>	TGGGGAGGGTGGGGAGGGTGGGGA
<i>bcl-2 2345</i>	GGGCGCGGGAGGAATTGGGCGGG
<i>bcl-2</i>	CGGGCGGGGAGGAAGGGGGCGGGAGC

*Stem-loop DNA. The bases colored as green form the stem part. Bases that are underlined are the A₂T₂ sequence, which widely known as the binding site for minor groove binders.

UV spectroscopy studies of DMZ binding to G quadruplexes and duplex DNA

We initiated our study by testing if DMZ or analogs could compete with a known G-quadruplex ligand, such as the fluorogenic N-methyl mesoporphyrin IX (NMM), in binding to *c-kit1* (see SI, Figure S1). Having obtained preliminary results that DMZ could indeed compete with NMM for *c-kit1* binding, we proceeded to perform a series of experiments to confirm whether the binding of DMZ to DNA G-quadruplexes was real. This started with studies of the interaction of DMZ with various G-quadruplex DNAs (*c-kit1*, *VEGF*, *bcl-2 2345* and *TBA*; see Table 1 for their sequences) using a conventional UV-visible absorption titration method employing an AT-rich duplex DNA, 8bp *AT*, as positive control. The absorption spectra of DMZ (10 μM) with different concentrations of G-quadruplex DNA (0-150 μM) are shown in Figure 2 and S2. Interestingly, gradually increasing the DNA concentration, resulted in a significant bathochromic shift (red shift) and a hypochromic effect on the 360 nm DMZ band for all of the tested G-quadruplexes (Figure 2 and S2). These observed effects in the UV-absorption spectra provided direct evidence for a strong interaction between DMZ and the G-quadruplex targets.




Figure 2. UV-titration studies showing binding of DMZ with DNA. (Left) Absorption spectra of DMZ (10 μM) upon titration with *c-kit1*. The concentrations of DNA are 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 150 μM . In the graph, 10 μM and 150 μM DNA concentrations are specifically emphasized as cyan and red line respectively. $[\text{KCl}] = 250 \text{ mM}$, Buffer = 50 mM Tris-HCl (pH 7.5). UV was measured at 20 $^{\circ}\text{C}$. (Right) Plot of absorbance at 360 nm against concentration ratio of DNA and Ligand (DMZ).

Importance of amidine moiety in DMZ binding to duplex DNA and G-quadruplexes.

Analysis of the crystal structure of DMZ/duplex DNA⁶⁰ complex (Figure 3) revealed that both amidine groups in DMZ make important and extensive contacts with the minor groove residues. Therefore we reasoned that the modification of one or both of the amidine groups could give an analog that would be incapable of binding to DNA minor groove. However it was unclear if the deletion of the amidine group would also reduce binding to G-quadruplexes.





Figure 3. DMZ interactions with duplex DNA (AT-rich). The amidine groups of DMZ make important hydrogen-bonding interactions with both DNA residues and water molecules in the minor groove of DNA (structure is from PDB#2DBE).

We synthesized two DMZ analogs (Triazene-1, which has one of the amidine groups in DMZ deleted and Triazene-2⁶¹, which does not contain any amidine group, see Figure 3). These DMZ analogs were then evaluated on the basis of their affinity for binding to both duplex and G-quadruplex DNA. The synthesis of Triazene-1 and Triazene-2, following precedent⁶¹, is outlined in Scheme 1. First, the diazonium salts of *p*-aminobenzamidine and aniline were generated by treating with sodium nitrite followed by their coupling with aniline to give Triazene-1 and Triazene-2 in good yields. Both of the synthesized triazenes were characterized by mass and NMR spectroscopy (see SI for spectral data).



Scheme 1: Synthesis of triazene ligands.

UV spectroscopy studies of Triazene-1 binding to G quadruplexes and duplex DNA

In qualitative UV-visible titration experiments, the absorbance maxima of Triazene-1 (10 μM) displayed a red shift with increasing concentrations of various G-quadruplexes (Figure 4 and S3), implying binding while Triazene-2, exhibited self-aggregation (data not shown here) and was not considered further. In contrast, when Triazene-1 was incubated with duplex DNA (Figure S3E), there was no evidence for a robust interactions between the Triazene-1 and an AT rich duplex DNA. Visual inspection of the UV titration experiments (compare Figures 2, S2 and 4, S3) revealed that DMZ had a higher affinity to the G-quadruplexes than Triazene-1, the DMZ analog having only one amidine group. The differences in affinity (selectivity) between DMZ and Triazene-1 for binding to duplex AT minor groove sites vs. G-quadruplex stacking or intercalation interactions were quantified using ITC experiments, *vide infra*.




Figure 4. UV-titration studies of binding of Triazine-1 with DNA. (Left) Absorption spectra of Triazine-1 (10 μM) upon titration with *c-kit1*. The concentrations of DNA are 0, 0.25, 1.5, 3, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 150 μM . In the graph, 10 μM and 150 μM DNA concentration is specifically emphasized as cyan and red line. $[\text{KCl}] = 250 \text{ mM}$, Buffer = 50 mM Tris-HCl (pH 7.5). UV was measured at 20 $^{\circ}\text{C}$. (Right) Plot of absorbance at 360 nm against concentration ratio of DNA and Ligand (Triazine-1).

NMR analysis of binding of DMZ and Triazene-1 to DNA

To provide direct evidence for the binding of DMZ and Triazene-1 to *c-kit1* (G-quadruplex) and duplex DNA, we performed ^1H -NMR titration experiments. Xu and co-workers used NMR to investigate the binding of a cyanine dye to *c-kit1* so we decided to start with *c-kit1*, based on this precedent^{18,46}. In general, the guanine imino protons resonate between 10.0 to 12.5 ppm in a quadruplex matrix and this represents guanine $\text{NH}\cdots\text{O}$ hydrogen bonds in the Hoogsteen alignments of G-quartets. Upon binding of small molecules, the chemical environment around these imino protons changes, resulting in changes in their NMR chemical shifts. Figure 5A shows the NMR spectra of the guanine imino protons of *c-kit1* in presence of the ligands, DMZ and Triazene-1 in 90% $\text{H}_2\text{O}/\text{D}_2\text{O}$. The chemical shifts for the guanine imino protons in the spectrum of *c-kit1* alone (Figure 5A), [ligand]:[*c-kit1*] = 0:1) was assigned based on the earlier work⁴⁶. The NMR titration spectra of DMZ and Triazene-1 with *c-kit1* show significant decreases in the peak intensities and line-broadening in the imino proton spectra (Figure 5A). These results demonstrate direct binding of DMZ and Triazene-1 to *c-kit1* (NMR resonances between 11.1 and 11.4 ppm are different between the case with no ligand added and when DMZ or triazene are added), consistent with our UV-visible titration experiments (Figures 2, S2 and 4, S3). When DMZ or Triazene-1 was added to *c-kit1*, the chemical shifts associated with the imino protons of G6, G10 and G2 did not change thereby excluding the possibility of end-stacking with the 5'-terminal tetrad of the quadruplex. Other NMR titration experiments with other G-quadruplexes, such as *VEGF* and *bcl-2 2345* did not give stable baselines (data not shown), probably due to aggregation of the ligand/DNA complex. Despite this technical difficulty, the *c-kit1* NMR titration data provide good evidence that DMZ does indeed bind to G-quadruplex DNA.




Figure 5. $^1\text{H-NMR}$ spectra of DNA incubated with ligands. $[\text{DMZ}]$ or $[\text{Triazene-1}] = 150 \mu\text{M}$, $[\text{DNA}] = 300 \mu\text{M}$ (ratio ligand : DNA = 0.5 : 1), $\text{D}_2\text{O} = 10 \%$, Buffer = 10 mM K-phosphate Buffer (pH 7.5), $[\text{NaCl}] = 137 \text{ mM}$, $[\text{EDTA}] = 1 \text{ mM}$. The ligand was incubated with DNA for 2 hr at 4°C before measurement. (A) DNA = *c-kit1*. (B) DNA = 8bp *AT*.

To further explore the interaction of the DMZ and Triazene-1 ligands with duplex DNA, NMR experiments in which 8bp-*AT* was incubated with the triazene ligands were performed as described for *c-kit1* above. In the case of duplex DNA (8bp *AT*), only DMZ (but not Triazene-1) showed significant changes in the imino region of spectrum of the duplex DNA (see Figure 5B). This is consistent with the UV titration data, which showed that Triazene-1 did not bind to AT-rich duplex DNA (see Figure 4 and S3).

NMR titration experiments have demonstrated that both DMZ and Triazene-1 bind to the *c-kit1* G-quadruplex. However, a definitive identification of the DMZ and Triazene-1 binding sites was not possible with the current NMR data (Figure 5A). Future work will be focused on obtaining

structural information for G-quadruplex DNA/DMZ (and/or DMZ analog) complexes via X-ray crystallography and/or NMR. Such studies would provide important information that will be used to design next generation triazene analogs that could have higher affinity and selectivity for G-quadruplex DNA.

Initial screening experiments employing UV and NMR titration methods, provided qualitative evidence that DMZ binds to both duplex and G-quadruplex DNA whereas Triazene-1 binds only to G-quadruplex DNA (and not AT rich duplex DNA) albeit with lower affinity than DMZ. However, neither the UV nor NMR methods are sensitive enough for the accurate determination of sub-micromolar binding constants. By employing ITC, we were able to determine the energetics for the interactions of DMZ and Triazene-1 with several commonly studied G-quadruplex constructs *hTel*, *c-myc*, *bcl-2*. We also used ITC to study the interactions between DMZ and Triazene-1 and two hairpin duplex DNA constructs, one having an A₂T₂ binding site, 7bp *HP-AT*, and one without the A₂T₂ site, 7bp *HP*. The sequences for these DNA targets were shown in Table 1.




Figure 6: Chemical structures of Diminazene aceturate (DMZ) and compound Triazene-1 in comparison to a chemical representation of a G-quartet.

DMZ/Triazene-1/*hTel22* complexes identified via mass spectroscopy




Figure 7: ESI mass spectrum for *hTel22* solution containing excess amount of DMZ (panel A) and ESI mass spectrum for *hTel22* solution containing excess amount of Triazene-1 (panel B). Y-axis is relative intensity and x-axis is m/z .

We have previously reported on the thermodynamic properties for the binding of several porphyrins and porphyrin derivatives to a variety of oncogene promoter sequence G-quadruplexes^{62,63}. We have repeatedly shown that the cationic porphyrin TMPyP4 binds to a number of G-quadruplexes and forms complexes having a saturation stoichiometry of $(n+1)$ where n is the number of G-tetrads in the G-quadruplex motif. In the case of the *c-myc*, *bcl-2*, and *kras* promoter sequence G-quadruplexes the saturation stoichiometry was determined to be 4 moles of TMPyP4 per mole of G4-DNA^{62, 63}. The DMZ (or Triazene-1) ligands are approximately half the size of TMPyP4 and we would speculate that two molecules of DMZ (or Triazene-1) could pi-stack with one G-tetrad (see Figure 6). The ESI mass spectra for a solution containing *hTel22* DNA in an excess amount of DMZ (panel A) and/or an excess amount of Triazene-1 (panel B) indicate that up to 8 molecules of these ligands can bind to one G-quadruplex. Three important features can be observed from panel A: first, there are no observable m/z peaks for free DNA; second, there are multiple m/z peaks indicating stoichiometry values larger than 4:1; and third, DMZ•*hTel22* complexes are observed with stoichiometries up to 8:1 as evidenced from the m/z peaks at 1843.3 and 2314.0. Similarly, the ESI mass spectrum shown in Figure 7 panel B for a solution containing *hTel22* in an excess amount of Triazene-1 also suggests a maximum stoichiometry of 8:1. However, there are notable differences between the data shown in panels A and B. The mass spectrum shown in panel B clearly exhibits the presence of some free or uncomplexed DNA as evidenced by m/z peaks at 1751.5 and 2328. The presence of free DNA

even in excess amounts of Triazene-1 ligand suggests a low binding affinity for the interaction of Triazene-1 with the *hTel22* G-quadruplex DNA.

Determination of DMZ and Triazene-1 binding constants to DNA using ITC

Typical raw ITC data for the titration of DMZ into five different DNA samples, 7bp *HP•AT*, 7 bp *HP*, 27mer *bcl-2*, 24mer *c-myc*, and 22mer *hTel*, are shown in Supplemental Figure S4. The thermodynamic parameters for the interaction of DMZ with these DNAs were obtained directly from the nonlinear regression fits of the raw ITC data to a one site, fractional one site, or three competitive sites thermodynamic binding model, depending on the number of species indicated in the thermograms. As shown in Figure S4, the binding of DMZ to 7bp *HP•AT* exhibits two different but independent overlapping binding modes and is reminiscent of the binding of netropsin (another AT minor groove binder) (64-67). The interaction of DMZ with the 7bp *HP* sequence, lacking the A_2T_2 site, exhibits weaker complex formation (and only one binding mode). The interactions between DMZ and 27mer *bcl-2* or 24mer *c-myc* are best described by at least three different binding processes. Typical nonlinear regression fits for the analysis of the binding of DMZ to 7bp *HP*, 7bp *HP-AT* and *bcl-2*, and *c-myc* are shown in Figure 8. The solid lines in Figure 8 represent the model lines using the best fit thermodynamic parameters for these ligand DNA interactions.




Figure 8. Typical nonlinear regression fits for the DMZ titrations of 7bp HP, and 7bp HP•AT are shown in panel A. The 7bp HP titration data are fit to a one site model and the 7bp HP•AT data are fit to a fractional two site model. Typical nonlinear regression fits for the DMZ titrations of 27mer *bcl-2* and 24mer *c-myc* are shown in panel B. Both the 27mer *bcl-2* and the 24mer *c-myc* DMZ titration data are fit to a three site model. The best fit parameters for the data shown in panels A and B are listed in Table 2.

Table 2: Thermodynamic data obtained from ITC experiments for the formation of the DMZ complexes with several different DNAs

Sequences	K_1 (M^{-1})	ΔH_1 (kcal/mol)	K_2 (M^{-1})	ΔH_2 (kcal/mol)	K_3 (M^{-1})	ΔH_3 (kcal/mol)
7bp HP•AT	9.8×10^5	-2.2	4.5×10^4	-8.7	-	-
7bp HP	-	-	1.8×10^4	-5.3	-	-
27mer <i>bcl-2</i>	8.8×10^8	-4.5	1.9×10^6	-2.2	6.4×10^4	-7.3
24mer <i>c-myc</i>	7.6×10^8	-5.5	1.9×10^7	-2.5	2.8×10^5	-4.7
22mer <i>hTel</i> Na ⁺	<i>nd</i>	<i>nd</i>	<i>nd</i>	<i>nd</i>	<i>nd</i>	<i>nd</i>
22mer <i>hTel</i> K ⁺	-	-	-	-	5.5×10^4	-3.8

nd =not determined

Note: K_1 , K_2 and K_3 are association constants. Dissociation constants, $K_d = 1/(K_1$ or K_2 or $K_3)$.

The thermodynamic parameters obtained from the ITC experiments (Figure S4 and fits Figure 8) reveal that DMZ binds to some G-quadruplex DNAs (for example *bcl-2* and *c-myc*) with dissociation constants as low as ~ 1 nM. This is of a similar affinity to that exhibited by guanidine phthalocyanines, considered to be one of the tightest binders of G-quadruplexes with K_d of ~ 2 nM¹⁷. Also the ligand TmpyP4, a classic G-tetrad binding ligand, binds to G-quadruplexes with $K_d \approx 2 \times 10^{-7}$ M^{62,68}, so the fact that DMZ binds to G-quadruplexes with 1 nM

dissociation constant is interesting. Of note is the observation that even the second dissociation constant, $K_{d2} \approx 5 \times 10^{-8}$ M, for the DMZ•*c-myc* complex is an order of magnitude smaller than the dissociation constant ($K_d \approx 1 \times 10^{-6}$ M) obtained for the DMZ•7bp *HP-AT* complex. Our K_d value for the DMZ•7 bp *HP-AT* complex is very similar to the dissociation constant ($K_d \approx 1 \times 10^{-6}$ M) determined in NMR experiments previously reported by Jenkins *et al.* for DMZ interactions with several types of B-DNAs containing the AT rich sequences⁶⁹. Interestingly, Jenkins *et al.* also mentioned the two overlapping events exhibited by the interactions of DMZ with AT rich sequences⁶⁹. The phenomenon of two overlapping sites observed for the AT rich sequence has been well documented and several possible mechanisms have been suggested, including: 1) two binding orientations of the minor groove binder in the DNA minor groove or 2) the formation of a complex in which one or more water molecules are trapped between the ligand binding in the minor groove and the floor of the DNA groove⁶⁴⁻⁶⁶.

The ITC heat data for the titrations of Triazene-1 to four different DNA sequences (a DNA hairpin and three G-quadruplex DNAs) are shown in Figure S5. Again, from visual inspection, it seems that the titration of Triazene-1 into Na^+ *hTel22* is calorimetrically silent while the addition of Triazene-1 to K^+ *hTel22* results in a significant exothermic signal. Notable differences between the DMZ and the Triazene-1 DNA titration experiments are that DMZ exhibits a much tighter binding affinity than Triazene-1, at least for the preferred G-quadruplexes, and Triazene-1 exhibits only a single binding event for its interactions with the *bcl-2*, and *c-myc* G-quadruplexes. In addition, the binding affinity for Triazene-1 interacting with K^+ *hTel22* is similar to the binding affinities for Triazene-1 interacting with either the *bcl-2* or *c-myc* G-quadruplexes. This result is in sharp contrast to DMZ which exhibits selectivity for the *bcl-2* or *c-myc* G-quadruplexes over K^+ *hTel22*. Triazene-1 binds to all of the tested G-quadruplexes with significantly lower affinity (4-5 orders of magnitude lower, compare Tables 2 and 3) than does DMZ. The binding affinity

for of Triazene-1 with 7bp *HP-AT* is also reduced by a factor of approximately 30. Furthermore, the second binding event observed in the DMZ binding to 7bp *HP-AT* is now eliminated in of the case of Triazene-1 interacting with the duplex DNA, 7bp *HP-AT*. Clearly, the removal of one amidine group from the parent DMZ compound to create the Triazene-1 ligand results in the loss of A₂T₂ recognition in the minor groove of the DNA. This was expected as the presence of two amidine groups is a common feature of several minor groove binders such as distamycin⁷⁰, netropsin^{64,66,70}, DAPI⁷¹ and pentamidine⁷². However, it remains to be answered why the loss of A₂T₂ recognition in the minor groove as exhibited by Triazene-1 also results in much lower binding affinities for the interactions of Triazene-1 with different G-quadruplexes.

Table 3: Thermodynamic data obtained from ITC experiments for the formation of the Triazene-1 complexes with several different DNAs

Sequences	K_1 (M ⁻¹)	ΔH_1 (kcal/mol)
7bp <i>HP-AT</i>	2.9×10^4	-1.9
7bp <i>HP</i>	<i>nd</i>	<i>nd</i>
27mer <i>bcl-2</i>	3.5×10^3	-1.8
24mer <i>c-myc</i>	3.6×10^4	-1.1
22mer <i>hTel</i> Na ⁺	<i>nd</i>	<i>nd</i>
22mer <i>hTel</i> K ⁺	2.1×10^3	-2.7

DMZ binding to G quadruplexes studied by circular dichroism (CD)

To determine the structural effects of the interactions between the DMZ and G-quadruplex DNAs, we performed a series of CD titration experiments in which DMZ was added to different G-quadruplexes. Figures 9 and 10 show the CD spectra for the titration of DMZ into three different G-quadruplexes, *bcl-2*, *c-myc*, and *hTel22*. These CD titrations were performed in K⁺ Tris buffer. Under these experimental buffer conditions (K⁺ salt), the CD spectra for the free WT *bcl-2*, WT *c-myc*, and *hTel22* G-quadruplexes exhibited characteristic CD spectral features that are similar to those previously reported in the literature^{49-51,62}. However, upon complexation with DMZ, the CD signals for both 27mer WT *bcl-2* and 24mer WT *c-myc* dramatically attenuated as

DMZ is added. A plausible explanation for this is that the inherent G-tetrad π - π stacking interactions in both the 27mer WT *bcl-2* and 24mer WT *c-myc* G-quadruplexes is weakened upon DMZ binding. In comparison to TMyP4, DMZ does not have the extended π -surfaces, which can interact extensively with the π system of the G-tetrad in either an end-stacking or intercalation mode. Perhaps the explanation for the surprisingly tight binding to specific G-quadruplexes is that DMZ is binding in the G-quadruplex groove or interacting in some way with loop bases. In the case of DMZ binding to K^+ *hTel22*, the addition of the DMZ appears to have very little effect on the parallel structure of *hTel22* G-quadruplex, see Figure 10. In the case of binding DMZ to duplex DNA, an induced DMZ CD signal is observed (see SI, Figure S6). However, there was no evidence for an induced ligand CD signal when DMZ was bound to the different G-quadruplexes. This lack of an induced CD is suggestive of end stacking or intercalative binding but not groove binding⁷³. A more detailed structural study of the DMZ G-quadruplex complexes could clarify these observations and help in the development of even more potent DMZ-based G-quadruplex binders.




Figure 9: CD spectra obtained from titration experiments for the additions of DMZ into a 27mer WT *bcl-2* (4.5 μM, panel A) and into 24mer WT *c-myc* (3.9 μM, panel B).




Figure 10: CD spectra obtained from titration experiment for the additions of DMZ into a *hTel22* (5.1 μM).

CONCLUSION

The finding that DMZ binds tightly to G-quadruplexes DNA is exciting for the following reasons:

a) DMZ does not readily form π -aggregates⁷⁴ and hence it is not as prone to non-specific binding

to other biomolecules as other aromatic-containing G-quadruplex ligands; b) the amidine groups on DMZ, improve aqueous solubility (an important factor for drugs); c) Unlike other structurally complex minor groove binders such as netropsin, DMZ has a simple structure and could be readily diversified and synthesized cheaply on a large scale and d) the amidine group, which is protonated at physiological pH, would facilitate drug permeation across lipid membranes that are externally decorated with anionic phosphates.

This work suggests that some of the toxicity or even the clinical benefits of DMZ may be due to its binding to G-quadruplexes, which has so far been overlooked. It is ironic that a ligand such as DMZ, which has long been considered as AT-rich specific minor groove binder does in fact strongly bind to G-quadruplexes. Future work will concentrate on making structural variants of DMZ that will include expanded aromatic systems and increased amidine groups for specific and potent G-quadruplex targeting. New classes of G-quadruplex ligands, which have low affinity for duplex DNA, are predicted to have potential applications in cancer therapy⁷⁵⁻⁷⁷.

Acknowledgement

Camille Dreyfus foundation and University of Maryland Graduate Dean's Dissertation Fellowship (JZ) supported this work.

Supporting Information Available. Competition assay between DMZ and NMM for G-quadruplex binding, UV titration studies of DNA with DMZ and Triazene-1, CD spectra of DMZ and Triazene-1 binding to duplex DNA and NMR spectra of Triazene-1 and Triazene-2 are

available. ITC raw data for the DMZ and Triazene-1 titrations of the HP and G-quadruplex DNAs.

REFERENCES

1. M. Gellert, M. N. Lipsett and D. R. Davies, *Proc. Natl. Acad. Sci. USA*, 1962, **48**, 2013.
2. M. L. Bochman, K. Paeschke and V. A. Zakian, *Nat. Rev. Genet.*, 2012, **13**, 770.
3. S. Kumari, A. Bugaut, J. L. Huppert and S. Balasubramanian, *Nat. Chem. Biol.*, 2007, **3**, 218.
4. M. D. Frank-Kamenetskii and S. M. Mirkin, *Annu. Rev. Biochem.*, 1995, **64**, 65.
5. V. Sklenar and J. Feigon, *Nature*, 1990, **345**, 836.
6. K. Gehring, J. L. Leroy and M. Gueron, *Nature*, 1993, **363**, 561.
7. T. A. Brooks, S. Kendrick and L. Hurley, *FEBS J.*, 2010, **277**, 3459.
8. G. W. Collie and G. N. Parkinson, *Chem. Soc. Rev.*, 2011, **40**, 5867.
9. M. Duchler, *J. Drug Target*, 2012, **20**, 389.
10. S. Balasubramanian, L. H. Hurley and S. Neidle, *Nat. Rev. Drug Discov.*, 2011, **10**, 261.
11. A. K. Todd, M. Johnston and S. Neidle, *Nucleic Acids Res.*, 2005, **33**, 2901.
12. J. L. Huppert and S. Balasubramanian, *Nucleic Acids Res.*, 2005, **33**, 2908.
13. Y. Xu, *Chem. Soc. Rev.*, 2011, **40**, 2719.
14. M. Wieland and J. S. Hartig, *Chem. Biol.*, 2007, **14**, 757.
15. M. Wieland and J. S. Hartig, *Nat. Protoc.*, 2009, **4**, 1632.
16. J. D. Beaudoin and J. P. Perreault, *Nucleic Acids Res.*, 2010, **38**, 7022.
17. J. Alzeer, B. R. Vummidi, P. J. Roth and N. W. Luedtke, *Angew. Chem. Int. Ed. Engl.*, 2009, **48**, 9362.
18. Q. Yang, J. Xiang, S. Yang, Q. Zhou, Q. Li, Y. Tang and G. Xu, *Chem. Commun. (Camb)*, 2009, 1103.
19. C. Schaffitzel, I. Berger, J. Postberg, J. Hanes, H. J. Lipps and A. Pluckthun, *Proc. Natl. Acad. Sci. USA*, 2001, **98**, 8572.
20. G. Biffi, D. Tannahill, J. McCafferty and S. Balasubramanian, *Nat. Chem.*, 2013, **5**, 182.
21. P. Agrawal, E. Hatzakis, K. Guo, M. Carver and D. Yang, *Nucleic Acids Res.*, 2013, **41**, 10584.
22. W. J. Chung, B. Heddi, M. Tera, K. Iida, K. Nagasawa and A. T. Phan, *J. Am. Chem. Soc.*, 2013, **135**, 13495.
23. I. T. Holder, M. Drescher and J. S. Hartig, *Bioorg. Med. Chem.*, 2013, **21**, 6156.
24. M. Azarkh, V. Singh, O. Okle, D. R. Dietrich, J. S. Hartig and M. Drescher, *ChemPhysChem*, 2012, **13**, 1444.
25. N. W. Kim, M. A. Piatyszek, K. R. Prowse, C. B. Harley, M. D. West, P. L. Ho, G. M. Coviello, W. E. Wright, S. L. Weinrich and J. W. Shay, *Science*, 1994, **266**, 2011.
26. A. M. Zahler, J. R. Williamson, T. R. Cech and D. M. Prescott, *Nature*, 1991, **350**, 718.
27. Y. Wang and D. J. Patel, *Structure*, 1993, **1**, 263.
28. G. N. Parkinson, M. P. Lee and S. Neidle, *Nature*, 2002, **417**, 876.
29. G. W. Collie, S. M. Haider, S. Neidle and G. N. Parkinson, *Nucleic Acids Res.*, 2010, **38**, 5569.
30. C. Bazzicalupi, M. Ferraroni, A. R. Bilia, F. Scheggi and P. Gratteri, *Nucleic Acids Res.*, 2013, **41**, 632.
31. Q. Li, J. F. Xiang, H. Zhang and Y. L. Tang, *Curr. Pharm. Des.*, 2012, **18**, 1973.

32. T. Vy Thi Le, S. Han, J. Chae and H. J. Park, *Curr. Pharm. Des.*, 2012, **18**, 1948.
33. I. Mender, S. Senturk, N. Ozgunes, K. C. Akcali, D. Kletsas, S. Gryaznov, A. Can, J. W. Shay and Z. G. Dikmen, *Int. J. Oncol.*, 2013, **42**, 1709.
34. S. M. Gowan, J. R. Harrison, L. Patterson, M. Valenti, M. A. Read, S. Neidle and L. R. Kelland, *Mol. Pharmacol.*, 2002, **61**, 1154.
35. J. I. Roh, Y. H. Sung and H. W. Lee, *Onco. Targets Ther.*, 2013, **6**, 1161.
36. A. Siddiqui-Jain, C. L. Grand, D. J. Bearss and L. H. Hurley, *Proc. Natl. Acad. Sci. U S A*, 2002, **99**, 11593.
37. J. Dai, T. S. Dexheimer, D. Chen, M. Carver, A. Ambrus, R. A. Jones and D. Yang, *J. Am. Chem. Soc.*, 2006, **128**, 1096.
38. S. Cogoi and L. E. Xodo, *Nucleic Acids Res.*, 2006, **34**, 2536.
39. S. Rankin, A. P. Reszka, J. Huppert, M. Zloh, G. N. Parkinson, A. K. Todd, S. Ladame, S. Balasubramanian and S. Neidle, *J. Am. Chem. Soc.*, 2005, **127**, 10584.
40. D. Sun, W. J. Liu, K. Guo, J. J. Rusche, S. Ebbinghaus, V. Gokhale and L. H. Hurley, *Mol. Cancer. Ther.*, 2008, **7**, 880.
41. M. Gunaratnam, S. Swank, S. M. Haider, K. Galesa, A. P. Reszka, M. Beltran, F. Cuenca, J. A. Fletcher and S. Neidle, *J. Med. Chem.*, 2009, **52**, 3774.
42. K. I. McLuckie, Z. A. Waller, D. A. Sanders, D. Alves, R. Rodriguez, J. Dash, G. J. McKenzie, A. R. Venkitaraman and S. Balasubramanian, *J. Am. Chem. Soc.*, 2011, **133**, 2658.
43. R. Martinez and L. Chacon-Garcia, *Curr. Med. Chem.*, 2005, **12**, 127;
44. T. M. Ou, Y. J. Lu, J. H. Tan, Z. S. Huang, K. Y. Wong and L. Q. Gu, *ChemMedChem*, 2008, **3**, 690.
45. W. I. Sundquist and S. Heaphy, *Proc. Natl. Acad. Sci. U S A*, 1993, **90**, 3393.
46. Q. Yang, J. Xiang, S. Yang, Q. Li, Q. Zhou, A. Guan, X. Zhang, H. Zhang, Y. Tang and G. Xu, *Nucleic Acids Res.*, 2010, **38**, 1022.
47. V. H. Le, R. Buscaglia, J. B. Chaires and E. A. Lewis, *Anal. Biochem.*, 2013, **434**, 233.
48. G. E. Plum, *Curr. Protoc. Nucleic Acid Chem.*, 2001, **Chapter 7**, Unit 7.3.
49. N. Nagesh, R. Buscaglia, J. M. Dettler and E. A. Lewis, *Biophys. J.*, 2010, **98**, 2628.
50. J. M. Dettler, R. Buscaglia, V. H. Le and E. A. Lewis, *Biophys. J.*, 2011, **100**, 1517.
51. J. S. Hudson, L. Ding, V. Le, E. Lewis and D. Graves, *Biochemistry*, 2014, DOI: 10.1021/bi500351u.
52. Z. Dong, S. Ekins and J. E. Polli, *Mol. Pharm.*, 2013, **10**, 1008.
53. P. B. Madrid, S. Chopra, I. D. Manger, L. Gilfillan, T. R. Keepers, A. C. Shurtleff, C. E. Green, L. V. Iyer, H. H. Dilks, R. A. Davey, A. A. Kolokoltssov, R. Carrion, Jr., J. L. Patterson, S. Bavari, R. G. Panchal, T. K. Warren, J. B. Wells, W. H. Moos, R. L. Burke and M. J. Tanga, *PLoS One*, 2013, **8**, e60579.
54. S. Cosconati, L. Marinelli, R. Trotta, A. Virno, S. De Tito, R. Romagnoli, B. Pagano, V. Limongelli, C. Giancola, P. G. Baraldi, L. Mayol, E. Novellino and A. Randazzo, *J. Am. Chem. Soc.*, 2010, **132**, 6425.
55. S. Cosconati, A. Rizzo, R. Trotta, B. Pagano, S. Iachettini, S. De Tito, I. Lauri, I. Fotticchia, M. Giustiniano, L. Marinelli, C. Giancola, E. Novellino, A. Biroccio and A. Randazzo, *J. Med. Chem.*, 2012, **55**, 9785.
56. L. Martino, A. Virno, B. Pagano, A. Virgilio, S. Di Micco, A. Galeone, C. Giancola, G. Bifulco, L. Mayol and A. Randazzo, *J. Am. Chem. Soc.*, 2007, **129**, 16048.
57. A. K. Jain and S. Bhattacharya, *Bioconjug. Chem.*, 2011, **22**, 2355.
58. M. P. Barrett, C. G. Gemmell and C. J. Suckling, *Pharmacol. Ther.*, 2013, **139**, 12.
59. I. Kelsey, S. Nakayama and H. O. Sintim, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 881.
60. D. G. Brown, M. R. Sanderson, J. V. Skelly, T. C. Jenkins, T. Brown, E. Garman, D. I. Stuart and S. Neidle, *EMBO J.*, 1990, **9**, 1329.
61. W. W. Hartman and T. B. Dickey, *Org. Synth.*, 1934, 24.

62. V. H. Le, N. Nagesh and E. A. Lewis, *PLoS One*, 2013, **8**, e72462.
63. G. B. Rowland, K. Barnett, J. I. Dupont, G. Akurathi, V. H. Le and E. A. Lewis, *Bioorg. Med. Chem.*, 2013, **21**, 7515.
64. M. W. Freyer, R. Buscaglia, D. Cashman, S. Hyslop, W. D. Wilson, J. B. Chaires and E. A. Lewis, *Biophys. Chem.*, 2007, **126**, 186.
65. M. W. Freyer, R. Buscaglia, B. Nguyen, W. D. Wilson and E. A. Lewis, *Anal. Biochem.*, 2006, **355**, 259.
66. M. W. Freyer, R. Buscaglia, A. Hollingsworth, J. Ramos, M. Blynn, R. Pratt, W. D. Wilson and E. A. Lewis, *Biophys. J.*, 2007, **92**, 2516.
67. E. A. Lewis, M. Munde, S. Wang, M. Rettig, V. Le, V. Machha and W. D. Wilson, *Nucleic Acids Res.*, 2011, **39**, 9649.
68. M. W. Freyer, R. Buscaglia, K. Kaplan, D. Cashman, L. H. Hurley and E. A. Lewis, *Biophys. J.*, 2007, **92**, 2007.
69. T. Jenkins, A. Lane, S. Neidle and D. Brown, *Eur. J. Biochem.*, 1993, **213**, 1175.
70. M. L. Kopka, C. Yoon, D. Goodsell, P. Pjura and R. E. Dickerson, *Proc. Natl. Acad. Sci. USA*, 1985, **82**, 1376.
71. W. Wilson, F. Tanious, H. Barton, L. Streckowski, D. Boykin and R. Jones, *J. Am. Chem. Soc.*, 1989, **111**, 5008.
72. I. Donkor, R. Tidwell and S. Jones, *J. Med. Chem.*, 1994, **37**, 4554.
73. M. Carvlin, N. Dattagupta and R. Fiel, *Biochem. Biophys. Res. Comm.*, 1982, **108**, 66.
74. D. S. Pilch, M. A. Kirolos, X. Liu, G. E. Plum and K. J. Breslauer, *Biochemistry*, 1995, **34**, 9962.
75. R. Haudecoeur, L. Stefan, F. Denat and D. Monchaud, *J. Am. Chem. Soc.*, 2013, **135**, 550.
76. O. P. Cetinkol, A. E. Engelhart, R. K. Nanjunda, W. D. Wilson and N. V. Hud, *ChemBioChem*, 2008, **9**, 1889.
77. T. A. Brooks and L. H. Hurley, *Genes Cancer*, 2010, **1**, 641.